newsfilter
← Latest News
GlobeNewswire·

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

—Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug's Unique Anti-Fibrotic,